ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimal Fluid Management in Adult Severe Malaria (DRIPICCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01936766
Recruitment Status : Unknown
Verified August 2014 by University of Oxford.
Recruitment status was:  Recruiting
First Posted : September 6, 2013
Last Update Posted : August 18, 2014
Sponsor:
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
Optimal fluid therapy in severe falciparum malaria has not been well defined, especially in resource poor settings where access to mechanical ventilation is limited. Recent studies suggest that liberal fluid resuscitation is harmful for severe malaria patients despite they often being hypovolemic on admission. In order to elucidate the minimum fluid therapy required to prevent complications in severe malaria, we will conduct a prospective observational study in adults with severe malaria, and also in adults with severe sepsis as a comparison group. The objective of this study is to describe the association between hemodynamic variations in conventional fluid management and the probability of developing acute kidney injury (AKI) or pulmonary edema in adults with severe malaria and severe sepsis. Hemodynamic measurements will be obtained by using transpulmonary thermodilution and arterial pulse contour analysis.

Condition or disease
Malaria Sepsis

  Show Detailed Description

Study Type : Observational [Patient Registry]
Estimated Enrollment : 120 participants
Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration: 14 Days
Official Title: Optimal Fluid Management in Adult Severe Malaria - Development of Renal Impairment and Pulmonary Edema in Complicated Malaria Under Conventional Fluid Strategy
Study Start Date : June 2013
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria Sepsis
U.S. FDA Resources




Primary Outcome Measures :
  1. Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index [ Time Frame: 24 hours ]
    The association between the mean Global End-Diastolic Volume Index (GEDVI) over the first 24 hours and (1) serum creatinine level, and (2) Extravascular Lung Water Index (EVLWI)


Secondary Outcome Measures :
  1. Association between the GEDVI,after conventional fluid resuscitation, and (1) serum creatinine level, (2) EVLWI [ Time Frame: 24 hours ]
    The association between the GEDVI at 6, 12, 18 or 24 hours after conventional fluid resuscitation and (1) serum creatinine level, (2) EVLWI

  2. Correlation between GEDVI and changes over time in plasma lactate level [ Time Frame: 72 hours ]
  3. Change in central venous oxygen saturation (ScvO2) in relation to GEDVI and its association with acid-base status [ Time Frame: 72 hours ]
  4. Incidence of pulmonary edema and ALI/ARDS [ Time Frame: 72 hours ]
    Incidence of pulmonary edema defined by increase of EVLWI (≥ 10 mL/kg) and ALI/ARDS in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid administration

  5. Incidence of AKI and induction rate of renal replacement therapy [ Time Frame: 72 hours ]
    Incidence of AKI defined by RIFLE or AKIN criteria and induction rate of renal replacement therapy in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid balance

  6. Time course of hemodynamic parameters in relation to fluid therapy [ Time Frame: 72 hours ]
    Time course of hemodynamic parameters, i.e. Cardiac Index (CI), Global Ejection Fraction (GEF), Stroke Volume Variation (SVV) in relation to fluid therapy

  7. Time course of respiratory parameters in relation to fluid therapy [ Time Frame: 72 hours ]
    Time course of respiratory parameters, i.e. PaO2/FiO2 ratio, Pulmonary Vascular Permeability Index (PVPI) in relation to fluid therapy

  8. Parasite burden in adults with severe malaria in relation to organ damage (renal, pulmonary) [ Time Frame: 72 hours ]
    Parasite burden, i.e. PfHRP2, peripheral blood parasitemia, parasite staging at enrollment in adults with severe malaria in relation to organ damage (renal, pulmonary)

  9. Evaluation of Biomarkers for early detection of ARDS [ Time Frame: 72 hours ]
    Evaluation of Biomarkers for early detection of ARDS in both severe malaria and sepsis (plasma transferrin, albumin, others)

  10. Correlation between GEDVI and clinical variables [ Time Frame: 72 hours ]
    Correlation between GEDVI and clinical variables including the jugular venous pressure (JVP) as a measure of volume status or passive leg raising as an indicator of fluid responsiveness

  11. Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis [ Time Frame: 72 hours ]
    Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis, based on the optimal GEDVI defined by primary outcome measures and secondary outcome measures No. 1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with severe malaria or severe sepsis admitted to the secondary or tertiary care center
Criteria

Inclusion Criteria:

A. Severe Malaria

  1. Any level of asexual form of P. falciparum parasitemia on blood smear
  2. Severe malaria with one or more of the following:

    i. Cerebral malaria (GCS < 11). ii. Renal impairment (Creatinine > 2mg/dL or Anuria) iii. Hypoglycaemia (Glucose < 40mg/dL) iv. Systolic blood pressure < 80mmHg with cool extremities v. Pulmonary edema vi. Venous bicarbonate < 15mmol/L vii. Venous lactate > 4mmol/L

  3. Age 16-65 years
  4. Written informed consent obtained from patient or attending relative.

B. Severe Sepsis

  1. Negative blood smear for any Plasmodium species
  2. Clinical signs of infection with two of following:

    i. Heart rate > 90/min ii. Respiratory rate > 20/min iii. Body temperature >38°C or <36°C iv. White blood cell count of > 12000/μL or < 4000/μL

  3. Severe sepsis with one or more of the following due to infection:

    i. Systolic blood pressure < 90mmHg despite fluid resuscitation ii. Lactate > 4mmol/L iii. Urine output < 0.5mL/kg/hour for > 2 hours despite fluid resuscitation iv. Acute lung injury with PaO2/FiO2 < 250 in the absence of pneumonia v. Acute lung injury with PaO2/FiO2 < 200 in the presence of pneumonia vi. Creatinine > 2mg/dL vii. Bilirubin > 2mg/dL viii. Platelet count < 100000/μL

  4. Age 16-65 years
  5. Written informed consent obtained from patient or attending relative

Exclusion Criteria:

A. Severe Malaria

  1. Patient or relative unable or unwilling to give informed consent
  2. Serious pre-existing disease The following exclusion criteria described below are applied to patient for whom invasive hemodynamic monitoring will be performed.
  3. Spontaneous bleeding or platelet count < 30000/μL on enrollment
  4. Pregnancy.
  5. Contraindication or unsuitable condition for thermodilution technique

B. Severe Sepsis

  1. Patient or relative unable or unwilling to give informed consent
  2. Serious pre-existing disease The following exclusion criteria described below are applied to patient for whom invasive hemodynamic monitoring will be performed.
  3. Spontaneous bleeding or platelet count < 30000/μL on enrollment
  4. Pregnancy.
  5. Contraindication or unsuitable condition for thermodilution technique

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01936766


Contacts
Contact: Arjen Dondorp, MD +66-2-203-6303 arjen@tropmedres.ac
Contact: Haruhiko Ishioka, MD +66-80-604-4255 haruhiko@tropmedres.ac

Locations
Bangladesh
Chittagong Medical College Hosiptal Recruiting
Chittagong, Bangladesh
Contact: Haruhiko Ishioka, MD    +880-178-250-5962    haruhiko@tropmedres.ac   
Sponsors and Collaborators
University of Oxford
Investigators
Principal Investigator: Arjen Dondorp, MD Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University

Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT01936766     History of Changes
Other Study ID Numbers: BAKMAL 1302
First Posted: September 6, 2013    Key Record Dates
Last Update Posted: August 18, 2014
Last Verified: August 2014

Keywords provided by University of Oxford:
malaria, falciparum
sepsis
fluid therapy
thermodilution
extravascular lung water
acute kidney injury

Additional relevant MeSH terms:
Malaria
Sepsis
Protozoan Infections
Parasitic Diseases
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes